| Line 18: | 
Line 18: | 
|   | == Resources from the international guideline community ==  |   | == Resources from the international guideline community ==  | 
|   |  |   |  | 
| − | === Example disclosure of interest forms: ===  | + | === Examples of disclosure of interest forms: ===  | 
|   | * [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i12 American Thoracic Society disclosure of interests form]  |   | * [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i12 American Thoracic Society disclosure of interests form]  | 
| − | * CADTH pan-Canadian Oncology Drug Review disclosure of interest form for panel members  | + | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-coi-guidelines-form.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for panel members]  | 
| − | * CADTH pan-Canadian Oncology Drug Review disclosure of interest form for clinicians  | + | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-clinician_coi-declaration.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for clinicians]  | 
| − | * CADTH pan-Canadian Oncology Drug Review disclosure of interest form for patient groups  | + | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-patientad-coi-declaratio.doc CADTH pan-Canadian Oncology Drug Review disclosure of interest form for patient groups]  | 
| − | * Canadian Task Force on Preventive Healthcare disclosure of interest form (see Appendix 1)  | + | * [https://canadiantaskforce.ca/wp-content/uploads/2016/12/procedural-manual-en_2014_Archived.pdf Canadian Task Force on Preventive Healthcare disclosure of interest form] (see Appendix 1)  | 
| − | * Cochrane Collaboration disclosure of interest form  | + | * [https://community.cochrane.org/sites/default/files/uploads/EPPR/Cochrane-COI-disclosure-form.pdf Cochrane Collaboration disclosure of interest form]  | 
|   | * US FDA financial disclosure report – Executive Branch  |   | * US FDA financial disclosure report – Executive Branch  | 
|   | * US FDA financial disclosure report – Special Government Employees  |   | * US FDA financial disclosure report – Special Government Employees  | 
| Line 40: | 
Line 40: | 
|   | * United States Preventive Services Task Force (USPSTF) disclosure of interest form  |   | * United States Preventive Services Task Force (USPSTF) disclosure of interest form  | 
|   |  |   |  | 
| − | === Example algorithms/process maps for COI management ===  | + | === Examples of algorithms/process maps for COI management ===  | 
|   | * American Thoracic Society COI resolution procedure  |   | * American Thoracic Society COI resolution procedure  | 
|   | * CADTH pan-Canadian Oncology Drug Review COI management overview (Appendix A)  |   | * CADTH pan-Canadian Oncology Drug Review COI management overview (Appendix A)  | 
| Line 48: | 
Line 48: | 
|   | * National Institute of Health and Care Excellence (UK) process for declaring interests (Appendix A)  |   | * National Institute of Health and Care Excellence (UK) process for declaring interests (Appendix A)  | 
|   |  |   |  | 
| − | === Example of published summaries of disclosures ===  | + | === Examples of published summaries of disclosures ===  | 
|   | o  Australian Technical Advisory Group on Immunisation disclosure summary  |   | o  Australian Technical Advisory Group on Immunisation disclosure summary  | 
|   |  |   |  | 
|   | o  Haute Authorité de Santé (France) examples of public disclosures of experts  |   | o  Haute Authorité de Santé (France) examples of public disclosures of experts  | 
|   |  |   |  | 
| − | === Example scales for assessing significance of COI ===  | + | === Examples of scales for assessing the significance of COI ===  | 
|   | o  American Thoracic Society method for evaluating significance of COI  |   | o  American Thoracic Society method for evaluating significance of COI  | 
|   |  |   |  | 
| Line 60: | 
Line 60: | 
|   | o  USPSTF COI significance and management table  |   | o  USPSTF COI significance and management table  | 
|   |  |   |  | 
| − | === GIN principles paper ===  | + | === [https://annals.org/aim/fullarticle/2450219/guidelines-international-network-principles-disclosure-interests-management-conflicts-guidelines GIN principles paper] ===  | 
|   |  |   |  | 
|   | == References ==  |   | == References ==  | 
|   | <references />  |   | <references />  |